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Summary
Fatty acid binding proteins (FABPs) are cytosolic fatty acid chaperones whose biological role and mechanisms of action
are not well understood. Here, we developed mice with targeted mutations in two related adipocyte FABPs, aP2 and mal1,
to resolve their role in systemic lipid, glucose, and energy metabolism. Mice lacking aP2 and mal1 exhibited a striking
phenotype with strong protection from diet-induced obesity, insulin resistance, type 2 diabetes, and fatty liver disease.
These mice have altered cellular and systemic lipid transport and composition, leading to enhanced insulin receptor
signaling, enhanced muscle AMP-activated kinase (AMP-K) activity, and dramatically reduced liver stearoyl-CoA desatur-
ase-1 (SCD-1) activity underlying their phenotype. Taken together with the previously reported strong protection against
atherosclerosis, these results demonstrate that adipocyte/macrophage FABPs have a robust impact on multiple compo-
nents of metabolic syndrome, integrating metabolic and inflammatory responses in mice and constituting a powerful
target for the treatment of these diseases.Introduction
Adipose tissue plays a critical role in energy homeostasis and
an array of endocrine functions. Obesity, characterized by ex-
cess accumulation of adipose tissue, is detrimental to many
systems and involved in the pathogenesis of multiple human
diseases (Saltiel, 2001; Spiegelman and Flier, 2001). These as-
sociated pathologies include insulin resistance, type 2 diabe-
tes, dyslipidemia, cardiovascular disease, and fatty infiltration
of the liver (Shulman, 2000; Tilg and Diehl, 2000). Currently,
more than 64.5% of the adult population in the United States
are overweight (Skyler and Oddo, 2002), and obesity and type
2 diabetes are the leading metabolic diseases worldwide
(Flegal et al., 1998; Zimmet et al., 2001). The incidence and the
impact of this disease cluster, also referred to as metabolic
syndrome, have risen to alarming proportions, and there is
great need for therapeutic and preventive measures against
these major health threats.
The systemic regulation of adiposity is controlled at many
levels by mechanisms endogenous both to adipocytes and to
paracrine and endocrine links with the central nervous system
and other metabolically critical sites such as muscle and liver
tissues. Lipids and their derivatives, as well as numerous cyto-
kines and hormones, are important to the function of these net-
works in health and disease (Friedman and Halaas, 1998; Mat-CELL METABOLISM : FEBRUARY 2005 · VOL. 1 · COPYRIGHT © 2005 Esuzawa et al., 1999; Sethi and Hotamisligil, 1999; Shulman,
2000). Obesity is associated with abnormalities of these func-
tional networks at many levels, including aberrant production
and/or abnormal function of most of these mediators, leading
to an array of associated pathologies (Friedman and Halaas,
1998; Sethi and Hotamisligil, 1999; Shulman, 2000). It is still
not fully clear why these pathologies and complications cluster
around obesity to establish the phenotype known as meta-
bolic syndrome.
Adipocytes are active sites of lipid metabolism involving
storage, mobilization, and transport of lipids as well as utiliza-
tion of lipid-mediated signaling pathways. These cells contain
high levels of a cytosolic fatty acid binding protein (FABP)
called aP2 (Bernlohr et al., 1999). It is generally accepted that
cytosolic FABPs in general, and aP2 in particular, facilitate the
utilization of lipids in metabolic pathways in adipocytes and
other cells. It is therefore likely that FABPs serve as a critical
link between lipid metabolism, hormone action, and cellular
functions in adipocytes and other cell types and thus contrib-
ute to systemic energy homeostasis. However, the definitive
biology and mechanisms of action of FABPs remain poorly
understood. Earlier studies have indicated a role for aP2 in glu-
cose metabolism (Hotamisligil et al., 1996; Scheja et al., 1999;
Uysal et al., 2000). Mice deficient in aP2, despite gaining more
weight, exhibit a modest increase in insulin sensitivity in theLSEVIER INC. DOI 10.1016/j.cmet.2004.12.008 107
A R T I C L Econtext of obesity with no protection from fatty liver disease.
More recently, a significant impact of this protein on the devel-
opment of atherosclerosis through modification of macrophage
inflammatory responses and cholesterol metabolism was ob-
served (Boord et al., 2002; Makowski et al., 2001). A second
FABP isoform, mal1, is also expressed in adipocytes. Mice de-
ficient in mal1 also exhibit a small increase in insulin sensitivity,
without changes in total body adiposity (Maeda et al., 2003).
Although mal1 is also expressed in macrophages in a similar
pattern with aP2, its role, if any, on atherosclerosis has not
yet been determined. Although normally found at low levels in
adipose tissue, mal1 is strongly upregulated in animals lacking
aP2, thus preventing full understanding of FABP function and
mechanism of action at this site and systemically (Hotamisligil
et al., 1996; Makowski et al., 2001; Scheja et al., 1999). To
overcome this limitation and examine the impact of FABPs on
adipocyte function and systemic metabolic homeostasis, we
developed mice lacking both aP2 and mal1 genes and exam-
ined the mechanisms underlying FABP function.
Results
Mice with combined aP2-mal1 deficiency
To address the impact of combined aP2-mal1 deficiency on
metabolic control, we have generated an intercross between
C57BL/6J-aP2−/− and C57BL/6J-mal1−/− mice (Maeda et al.,
2003). Although the estimated genetic distance between these
two genes was very close (0.1–0.15 cM), we were able to gen-
erate two recombination events between these loci out of 600
offspring in the F2 generation from a cross between aP2-
mal1−/+ (heterozygous mutant at both loci). The wild-type (wt)
and mutant alleles segregated in the expected Mendelian ra-
tios. In double mutant animals, aP2 and mal1 expression were
not detectable in various adipose depots (Figure 1A ). No com-
pensatory regulation in other major FABPs including liver, brain,
intestine, or heart isoforms were observed in adipose tissue of
aP2-mal1 null mice (data not shown). There was also no aP2
and mal1 expression in macrophages of double mutant mice
(data not shown). In immunoblotting experiments, no aP2 or
mal1 protein was detectable in the adipose tissue of aP2-
mal1−/− mice (Figure 1B). We also examined the total cytosolic
fatty acid binding capacity in adipose tissue of aP2-mal1−/−
and wt mice. As shown in Figure 1C, there was a significant
reduction in fatty acid binding capacity in aP2-mal1−/− adipose
tissue. This reduction was not evident in the single aP2- or
mal1-deficient mice, where there was only a small decrease in
adipose tissue fatty acid binding capacity in aP2−/− animals
and no difference was evident in mal1−/− mice compared to
wild-type controls. There was no reduction in fatty acid binding
capacity in muscle of aP2-mal1-deficient mice, and the liver
fatty acid binding activity was slightly increased as compared
to wt (data not shown), suggesting that the loss of fatty acid
binding is specific to adipose tissue.
There was no gross apparent abnormality in reproduction,
growth, and development of aP2-mal1−/− mice under standard
laboratory conditions in either sex. Besides these initial obser-
vations, the rest of the detailed experimentation was performed
in males. Despite normal axial growth, aP2-mal1−/− mice exhib-
ited a reduction (5.2%) in total body weight compared to con-
trols, suggesting that the absence of these FABPs might influ-108ence adiposity (see below). This weight difference was not ob-
served in the aP2−/− or mal1−/− mice on regular diet (Figure 1D).
To address the possibility of protection from excess adiposity
thoroughly, we placed aP2-mal1−/− mice and wt littermates on
a hig-fat (50% of total calories derived from fat) and high-calo-
rie diet (5286 kcal/kg, Bioserve, NJ) along with a control group
in each genotype on regular rodent diet. On a high-fat diet, wt
control mice developed marked obesity compared to mice fed
a regular rodent diet (Figure 1D). However, in the aP2-mal1−/−
group, weight gain on the high-fat diet was significantly re-
duced (15%–16% between ages 8 and 20 weeks, Figure 1D).
Again, this pattern differed from the single aP2−/− and mal1−/−
mice. Mice with mal1 mutation exhibited a smaller decrease in
total body weight, whereas, in aP2−/− animal’s body, weight
was higher than the wt controls on high-fat diet (Figure 1D).
Adiposity in aP2-mal1-deficient mice
We next assessed whether this reduction in total body weight
gain aP2-mal1−/− is related to local and systemic alterations in
adiposity by performing whole-body nuclear magnetic reso-
nance (NMR) spectroscopy (Figure 1E) and dual energy X-ray
absorption (DEXA) analyses (Figure 1F). In imaging studies by
NMR, all fat compartments were clearly reduced in the sec-
tions prepared at the levels of neck, around kidneys, abdominal
region, and subcutaneous depots of the aP2-mal1−/− mice
compared to the wt controls on both regular and high-fat-diet-
fed animals (Figure 1E). In fact, the body composition of wt
mice on regular diet and aP2-mal1−/− mice on high-fat diet ap-
peared quite similar. To investigate the level of total systemic
reduction in adiposity, we next examined total body composi-
tion by DEXA and proton NMR (Sjogren et al., 2001). There was
no significant difference in total body composition in aP2−/− or
mal1−/− mice compared to wt controls on either regular or high-
fat diet (Figure 1F). However, DEXA analyses demonstrated
significantly reduced total body adipose mass in aP2-mal1−/−
mice both on regular and high-fat diet (Figure 1F). These results
were also confirmed with total body proton NMR analysis (Ra-
zani et al., 2002), which exhibited 22% and 25.8% reduction in
total body fat in aP2-mal1−/− mice compared to wt controls on
regular and high-fat diet, respectively.
Energy metabolism in aP2-mal1−/− mice
The two major components contributing to the systemic en-
ergy balance and adiposity are energy intake and expenditure.
To identify potential contributors to body weight reduction,
food intake and energy expenditure were examined in aP2-
mal1−/− and wt groups. Despite being leaner, the aP2-mal1−/−
mice had no reduction in total daily food intake. In fact, these
animals consumed slightly more food, although this difference
was statistically insignificant between genotypes on either reg-
ular or high-fat diet (see Figure S1A in the Supplemental Data
available with this article online, and data not shown). When
corrected for body weight, the increase in total food intake be-
came more evident (Figure S1A). During the period of food in-
take measurements, body weight difference was again appar-
ent between genotypes (Figure S1B). There was also no
difference in rectal temperature (Figure S1C) or fecal lipid
content (Figure S1D) between genotypes, ruling out fever or
intestinal malabsorption as underlying causes of reduced adi-CELL METABOLISM : FEBRUARY 2005
Fatty Acid Binding Proteins and Metabolic SyndromeFigure 1. Total adiposity, adipose depot distribution,
and expression of FABPs in aP2-mal1-deficient mice
A) Lack of aP2 and mal1 mRNA expression in aP2-
mal1-deficient mice. Probes for aP2 and mal1 FABP
isoforms were hybridized with total RNA from epi-
didymal (EF) and subcutaneous fat (SF) of 16-week-
old, wild-type (wt), and aP2-mal1-deficient (AM−/−)
mice. Loading and integrity of RNA is shown with
EtBr staining. B) Lack of adipose tissue aP2 and
mal1 proteins in aP2-mal1-deficient mice. Immu-
noblots with isotype-specific antibodies showing
the absence of aP2 and/or mal1 proteins in wt,
aP2−/− (A−/−), mal1−/− (M−/−), and aP2-mal1-deficient
mice. C) Adipose fatty acid binding activity of wt
(green), A−/− (pink), M−/− (orange), and AM−/− (blue)
mice. Values for each mutant strain are expressed
as percentage of wt. Textured part of each column
represents predicted nonspecific binding (see Sup-
plemental Experimental Procedures). D) Growth
curves of wt (green), A−/− (pink), M−/− (orange), and
AM−/− (blue) mice on regular (RD) or high-fat diet
(HFD). Obesity is induced by high-fat diet starting
from 3 weeks of age. a = AM−/− is statistically signifi-
cantly different from A−/−; b = AM−/− is statistically
significantly different from wt; c = AM−/− is statistic-
ally significantly different from M−/−; d = AM−/− is
statistically significantly different from wt, A−/−, and
M−/− mice. E) Nuclear magnetic resonance (NMR)
sections obtained from the same groups of mice
shown in (D) at 16 weeks of age. F) Total body com-
position analysis by dual energy X-ray absorption-
metry (DEXA). Black bars indicate lean body mass,
and the yellow bars indicate fat mass. Data on all
mice used in DEXA experiments are also shown on
the upper portion of the graph by filled circles. G)
CO2 production and (H) O2 consumption of AM−/−
and wt mice determined by indirect calorimetry. Er-
ror bars represent the SEM. Asterisk, p < 0.05.posity in FABP-deficient animals.
We next determined whether differences in energy expendi-
ture in aP2-mal1-deficient animals could account for the differ-
ences in adiposity by performing indirect calorimetry studies
and determination of physical activity. In these studies, aP2-CELL METABOLISM : FEBRUARY 2005mal1-deficient mice exhibited similar rates of physical activity
in continuous 48 hr period measurements (Figure S1E). How-
ever, there was a significant increase in the rates of carbon
dioxide production (Figure 1G) and oxygen consumption (Fig-
ure 1H) in aP2-mal1−/− mice compared to wt controls. Taken109
A R T I C L Etogether, these data demonstrate that the primary metabolic
mechanism underlying the reduction in adiposity in aP2-mal1−/−
mice is increased energy expenditure.
Adipose tissue, lipid transport and distribution,
and adipocytokines in aP2-mal1-deficient mice
There was no significant difference in the extent of adipocyte
differentiation in aP2-mal1−/− mouse embryonic fibroblasts
compared to wt or heterozygous cells (data not shown). In light
of these observations, we next considered the possibility that
the combined lack of aP2 and mal1 alters the lipid profiles in
tissues due to their differential affinity and transport properties.
To address this question, we isolated the fatty acid fraction
from two different adipose tissue depots and quantified indivi-
dual fatty acids. We also performed parallel fatty acid profiling
experiments in muscle and liver tissues and serum. These ex-
periments revealed significant differences in fatty acid distribu-
tion between wt and aP2-mal1−/− mice (Figures 2A and 2B).
Among saturated fatty acids, accumulation of shorter chain
fatty acids such as myristic acid (14:0) was favored in aP2-
mal1−/− adipose and muscle tissues compared to stearic (18:0)
or palmitic acid (16:0). Strikingly, liver exhibited the complete
opposite pattern of fatty acid distribution between aP2-mal1−/−
mice and wt controls. Among monounsaturated fatty acids, the
ratios strongly favored myristoleic (14:1n-5c) and palmitoleic
(16:1n-7c) acid in adipose and muscle tissues (Figure 2B). The
lipid profiles were similar between the two adipose tissue de-
pots studied. This distribution was not present in liver or se-
rum, where monounsaturated fatty acid ratio was extremely
low compared to longer chain length fatty acids in aP2-mal1−/−
mice. In a separate experiment, we also measured the adipose
tissue lipid composition of all of the same fractions quantita-
tively and obtained similar results in lipid distribution (data not
shown).
Next, we examined whether the adipocyte FABPs regulate
fatty acid transport properties, which might underlie the alter-
ations observed in lipid composition in aP2-mal1−/− adipose
tissue. Typically, fatty acid uptake experiments are performed
by palmitic acid (16:0). When we also used this fatty acid in
initial experiments, we have not observed any differences be-
tween genotypes (Figure 2C). As adipose tissue palmitic acid
levels are also similar between genotypes, we next asked
whether fatty acid uptake differs between aP2-mal1-deficient
and wt adipocytes for fatty acids with different chain lengths.
Interestingly, these experiments demonstrated that the uptake
of stearic acid (18:0) was significantly reduced in aP2-mal1-
deficient adipocytes. In contrast, fatty acid uptake was in-
creased for lauric acid (12:0). These data provide a potential
mechanism for the alterations in lipid composition in adipose
tissue via chain length-selective regulation of fatty acid traffick-
ing in adipocytes. In biochemical measurements of steady-
state serum lipids, we observed a modest decrease in circu-
lating triglycerides and a modest increase in free fatty acid
concentrations (Table S1). These changes were observed in
animals on both regular and high-fat diets. There was no signif-
icant alteration in serum glycerol or total cholesterol levels be-
tween genotypes.
We also investigated the expression patterns of several adi-
pose-derived hormones in adipose tissues from mice on high-
fat diet to determine the impact of these compositional changes
on adipocytokines. There were reductions in the expression of110adiponectin (62%), leptin (52%), and TNFα (70%) mRNAs in
aP2-mal1−/− mice (Figure 2D) in the epididymal adipose depot
compared to wt controls. Serum leptin level was also signifi-
cantly (63.0%) reduced in aP2-mal1−/− mice (13.04 ± 1.1 ver-
sus 4.8 ± 0.5 ng/ml in wt and aP2-mal1−/− mice, respectively,
p < 0.005, Figure 2E). Interestingly, the serum level of adipo-
nectin was also decreased (15.1%) in the aP2-mal1−/− animals
(25.18 ± 1.0 versus 21.4 ± 1.1 µg/ml in wt and aP2-mal1−/−
mice, respectively, p < 0.05, Figure 2F). This is surprising, since
adiponectin levels typically correlate negatively with body
weight (Arita et al., 1999). Finally, there was no detectable cir-
culating TNFα in the aP2-mal1−/− mice, whereas, in wt mice on
high-fat diet, TNFα protein was detectable in serum (27.3 ± 7
pg/ml). These results demonstrate that FABP deficiency results
in alterations in lipids and adipocytokines, the two major
classes of metabolic regulators derived from adipose tissue.
These changes also create a milieu that might have a strong
impact on systemic insulin action, which is addressed below.
Protection against insulin resistance in aP2-mal1−/− mice
Rising blood glucose and insulin levels in animals on high-fat
diet are an indicator of obesity-induced insulin resistance and
development of type 2 diabetes. Measurement of blood glu-
cose levels demonstrated that obese wt mice developed
hyperglycemia compared to lean controls (330 ± 7.2 versus
197 ± 6.1 mg/dl, p < 0.001). However, on the high-fat diet, aP2-
mal1−/− mice had significantly lower blood glucose concentra-
tions compared to wt controls (Figure 3A). In fact, throughout
the experiment, the blood glucose levels in aP2-mal1−/− mice
on high-fat diet were indistinguishable from those of lean wt
animals on regular diet (196 ± 5.7 verus 197 ± 6.1 mg/dl). Blood
glucose levels on regular diet were also lower (163 ± 5.4
mg/dl), although to a lesser extent, in the aP2-mal1−/− mice
compared to wt controls. Wt mice on high-fat diet developed
hyperinsulinemia compared to those on regular diet (3.2 ± 0.7
versus 0.65 ± 0.2 ng/ml p < 0.001). Blood insulin levels in aP2-
mal1−/− mice were significantly lower throughout the experi-
mental period compared to wt controls (Figure 3B) and were
indistinguishable from those of wt lean mice (0.66 ± 0.1 versus
0.65 ± 0.2). Hence, these results indicate that the aP2-mal1-
deficient animals might be protected from the development of
high-fat-diet-induced insulin resistance and diabetes.
To further investigate systemic insulin sensitivity, we per-
formed insulin (ITT) and glucose (GTT) tolerance tests in aP2-
mal1−/− mice and wt controls. Insulin resistance was evident in
wt mice upon high-fat diet. As shown in Figure 3C, the hypo-
glycemic response to insulin in aP2-mal1−/− mice on high-fat
diet was indistinguishable from control animals on regular diet.
GTT also revealed a higher degree of hyperglycemia in wt ani-
mals throughout the experiment, compared to aP2-mal−/− mice
on high-fat diet (Figure 3D). In this test, the responses recorded
in aP2-mal1−/− mice did not reach those of lean controls. While
these responses were also improved in aP2−/− and mal1−/−
mice on high-fat diet, these changes were significantly smaller
in magnitude (Figures 3E and 3F). The increase in insulin sensi-
tivity in ITT was most dramatic in aP2-mal1−/− mice on high-
fat diet. The magnitude of increase in insulin responsiveness in
the aP2−/− mice (38%) was smaller than that in aP2-mal1−/−
mice (55%) but greater than the mal1−/− animals (15%) on the
high-fat diet (Figure 3E). Similar to the results of ITT, the magni-
tude of increase in glucose disposal relative to the wt controlsCELL METABOLISM : FEBRUARY 2005
Fatty Acid Binding Proteins and Metabolic SyndromeFigure 2. Adipocyte fatty acid uptake, gene expres-
sion, and tissue lipid composition in aP2-mal1-defi-
cient mice
Saturated (A) and nonsaturated (B) fatty acid com-
position in subcutaneous (SC) and epididymal (EPI)
adipose, muscle, liver tissues, and serum in aP2-
mal1-deficient (AM−/−) mice compared to wild-type
(wt) controls. C) Uptake of lauric (C12), myristic
(C14), palmitic (C16), and stearic (C18) by primary
adipocytes isolated from wt or AM−/− mice. Values
for FABP-deficient mice expressed as percentage of
wt. Error bars represent the SEM. Asterisk, p < 0.01.
D) Steady-state mRNA expression patterns in epi-
didymal adipose tissues of AM−/− and wt mice.
Gene expression is determined by Northern blot
analyses as in Figure 1. E) Serum level of leptin and
(F) adiponectin plotted against body weight at 12
weeks of age on high-fat diet in wt and AM−/− mice.in the aP2−/− mice (28%) was smaller than the aP2-mal1−/−
mice (45%) but greater than the mal1−/− animals (9%) on high-
fat diet (Figure 3D). These results demonstrate that the com-
bined deficiency of aP2 and mal1 resulted in a significant
protection from high-fat-diet-induced insulin resistance and
type 2 diabetes.CELL METABOLISM : FEBRUARY 2005Muscle lipids, AMP-activated kinase activity, and insulin
sensitivity in ap2-mal1-deficient mice
The reduction in body weight and adiposity in FABP-deficient
mice could have an influence on the insulin sensitivity. How-
ever, the impact of FABP deficiency on systemic insulin sensi-
tivity is disproportionate to its effects on body weight and111
A R T I C L EFigure 3. Glucose metabolism in aP2-mal1-deficient mice
Blood glucose (A) and insulin (B) levels in wt (blue triangle solid line, n = 17) and aP2-mal1-deficient (AM−/−, blue triangle dashed line, n = 14) mice on regular diet and
wt (green square solid line, n = 12) and AM−/− (green square dashed line, n = 13) mice on high-fat diet. Glucose and insulin were measured after 6 hr daytime food
withdrawal. Insulin (C) and glucose (D) tolerance tests performed on wt and AM−/− mice on regular and high-fat diet. Asterisk, p < 0.05. Insulin (E) and glucose (F)
tolerance test in all mutants expressed as integrated area under the glucose disposal curves (AUC) for each genotype relative to wt controls on high-fat diet.
Experiments are performed on 14–16 weeks of age at fasting state, n = 6–8 in each group. Error bars represent the SEM. *a = M−/− is statistically significantly different
from wt; *b = A−/− is statistically significantly different from wt and M−/−; *c = AM−/− is statistically significantly different from wt, A−/−, and M−/− mice.hence should involve an independent direct impact on insulin
action. The dramatic increase in insulin sensitivity as well as
changes in energy homeostasis, lipid profiles, and adipocyto-
kines all point to the involvement of muscle tissue in the phe-
notype of FABP-deficient animals. A feasible mechanism in this
context is the alterations of lipid content and/or composition
of the muscle (as shown earlier), which in turn activate insulin
receptor signaling cascades and/or other pathways related to
energy expenditure. To address this model, we first examined112muscle lipid content. In fact, total muscle triglyceride content
was significantly lower (Figure 4A) in the aP2-mal1−/− mice
compared to wt controls (0.044 ± 0.006 versus 0.066 ± 0.01
mg/g, respectively, p < 0.005). As stated before, there was also
a shift in the distribution of saturated fatty acids favoring in the
aP2-mal1−/− animals the shorter chain myristic (14:0) versus
longer chain stearic (18:0) acid (Figure 2A). We reasoned that
this lipid environment would be favorable to insulin action and
hence examined insulin sensitivity in isolated muscle strips andCELL METABOLISM : FEBRUARY 2005
Fatty Acid Binding Proteins and Metabolic SyndromeFigure 4. Tissue lipid content and insulin responsiveness in aP2-mal1 deficiency
A) Triglyceride content of skeletal muscle obtained from aP2-mal1−/− (AM−/−) and wt mice on high-fat diet.
B) Baseline and insulin-stimulated glucose transport in isolated muscle strips obtained from aP2-mal1−/− (AM−/−) and wild-type (wt) mice on both regular and high-
fat diet.
C) The effects of fatty acid chain length on baseline and insulin-stimulated phosphorylation of Akt in cultured C2C12 myocytes.
D) Baseline and insulin-stimulated phosphorylation of Akt in the muscle tissue of AM−/− and wt mice on regular (RD) and high-fat diet in vivo (HFD). The numbers under
the blot show the quantitation of the phospho-Akt signal on high-fat diet in phosphoimager.
E) Baseline and insulin-stimulated glucose transport in isolated adipocytes from AM−/− and wt mice on both regular and high-fat diet.
F) Baseline and insulin-stimulated Akt phosphorylation in the adipose tissues of AM−/− and wt mice on regular and high-fat diet in vivo. The numbers under the blot
show the quantitation of the phospho-Akt signal on high -fat diet in phosphoimager. Error bars represent the SEM. Asterisk, p < 0.05.muscle tissues obtained from wt and aP2-mal1−/− mice. In ex-
periments with isolated primary muscle strips from wt and aP2-
mal1−/− mice, we observed a significant increase in insulin-
stimulated glucose transport capacity in aP2-mal1−/− muscle
cells (Figure 4B). This increase was evident in muscles ob-
tained from mice under both regular and high-fat diet (Figure
4B) but more striking in the latter, indicating essentially com-
plete rescue of glucose transport capacity in aP2-mal1−/− cells
despite exposure to high-fat diet. We next asked whether insu-
lin action in muscle cells is altered as a function of the lipidCELL METABOLISM : FEBRUARY 2005environment observed in aP2-mal1−/− muscle tissue. To inves-
tigate this question, we incubated cultured muscle cells with a
variety of lipids and examined insulin-stimulated phosphoryla-
tion of Akt (Figure 4C). These experiments clearly showed that
insulin-stimulated phosphorylation of Akt was higher in the
presence of shorter chain (12:0 and 14:0) fatty acids and
strongly inhibited in the presence of longer chain (16:0 and
18:0) fatty acids (Figure 4C). These findings demonstrate that
lipid composition in the aP2-mal1−/− muscle tissue was highly
favorable for insulin action. We also studied insulin-stimulated113
A R T I C L Ephosphorylation of Akt in the muscle tissue of aP2-mal1−/− and
control mice on both regular and high-fat diet (Figure 4D). The
phospho-Akt levels were similar between genotypes in mice on
regular diet except for a small increase in baseline Akt phos-
phorylation in aP2-mal1−/− mice. There was, however, a signifi-
cant increase in phosphorylation of muscle Akt in aP2-mal1-
deficient animals on high-fat diet both before and following
insulin stimulation (Figure 4D). Similar results were also ob-
tained in adipose tissue, where both insulin-stimulated glucose
transport and Akt activation were strikingly increased in aP2-
mal1-deficient animals (Figures 4E and 4F). In adipose tissue,
the increase in baseline Akt phosphorylation in the lean aP2-
mal1−/− animals appeared more evident. These data clearly de-
monstrate that, at the molecular level, aP2-mal1 deficiency re-
sulted in striking protection from high-fat-induced inhibition of
insulin action in muscle and adipose tissues.
An important energy sensor in skeletal muscle is the AMP-
activated kinase (AMP-K). Interestingly, this kinase is targeted
by leptin, and its activation is a potential protective mechanism
against lipid accumulation. The fatty acid oxidation induced in
muscle by leptin and adiponectin (Fruebis et al., 2001; Muoio
et al., 1997) and potentially the protection against obesity and
diabetes might be related, at least in part, to their ability to
induce AMP-activated protein kinase activity (Minokoshi et al.,
2002; Winder and Hardie, 1999; Yamauchi et al., 2001). We
therefore determined whether AMP-K is differentially phos-
phorylated in muscle tissue of aP2-mal1−/− mice and wt con-
trols. Levels of total and phosphorylated AMP-K were mea-
sured in the soleus muscle by immunoblot analyses (Figure
5A). Quantification of immunoblot analyses demonstrated a
significant 2-fold increase in the amount of phosphorylated
AMP-K in soleus muscle from obese aP2-mal1−/− mice com-
pared to wt controls.
To examine the level of activation of AMP-K in muscle in
response to leptin, we administered recombinant leptin (1 mg/Figure 5. Phoshorylation of AMP-activated kinase
and fatty acid oxidation in muscle
A) Phosphorylation and total protein levels of AMP-
K in soleus muscle of aP2-mal1−/− (AM−/−) and wild-
type (wt) mice with high-fat-diet-induced obesity.
These experiments reflect baseline activity at 16
wError bars represent theeeks of age.
B) AMP-K-α1 activity in soleus muscle following 15
min saline (C) or leptin (L) treatment in AM−/− and wt
mice with high-fat-diet-induced obesity (n = 5–6 for
each condition).
C) AMP-K-α2 activity in soleus muscle under the
same conditions in (B). Asterisk, p < 0.05 *a = signif-
icantly different from baseline activity in wt controls;
*b = significantly different from both baseline and
stimulated activity in wt controls and also from
baseline activity in AM−/− mice.
D) The effects of fatty acid chain length on phos-
phorylation of AMP-K in cultured L6 myocytes.
AMP-K phosphorylation is detected by a phospho-
specific antibody.
E) Fatty acid oxidation in soleus muscle isolated
from AM−/− and wt mice. Error bars represent the
SEM. Asterisk, p < 0.05.114kg i.v.) to age- and sex-matched wt and aP2-mal1−/− mice on
high-fat diet. We then isolated the soleus muscle and deter-
mined the ability of leptin to activate this kinase. Leptin admin-
istration increased the AMP-K-α1 activity 50% over baseline in
wt mice (Figure 5B). At the baseline, aP2-mal1−/− mice exhib-
ited significantly increased (2.1-fold) AMP-K-α1 activity com-
pared to wt mice. In aP2-mal1−/− animals, leptin further stim-
ulated the AMP-K-α1 activity (70% over baseline) in soleus
muscle, which was significantly higher (2-fold) than leptin-stim-
ulated AMP-Kα1 activity in wt controls (Figure 5B). Leptin also
stimulated the AMP-Kα2 activity (4.1-fold over baseline) in wt
animals (Figure 5C). As reported, this was more potent com-
pared to leptin’s ability to stimulate the AMP-Kα1 isoform (Mi-
nokoshi et al., 2002). In aP2-mal1−/− animals, baseline AMP-
Kα2 activity in soleus muscle was significantly higher than wt
animals (3.9-fold) and already reached the levels observed in
the leptin-treated wt mice. Leptin treatment further stimulated
AMP-Kα2 to even higher levels over the already increased
baseline activity in aP2-mal1-deficient mice (Figure 5C). We
next asked whether the mechanism underlying the increase in
AMP-K activity might be the alterations in lipid composition. To
approach this question, we exposed cultured muscle cells to
fatty acids with various chain lengths and determined the
phosphorylation of AMP-K (Figure 5D). These experiments
demonstrated that phosphorylation of AMP-K was significantly
higher in the presence of shorter chain (12:0 and 14:0) fatty
acids and inhibited in the presence of longer chain (16:0 and
18:0) fatty acids (Figure 5D). Based on these observations, we
postulated that these alterations might lead to enhanced fatty
acid oxidation in muscle, which would be consistent with in-
creased metabolic rate and reduced body weight. To address
this, we determined fatty acid oxidation in soleus muscle strips
isolated from aP2-mal1−/− mice and wt control animals. These
experiments demonstrated significantly increased capability ofCELL METABOLISM : FEBRUARY 2005
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together, these data indicate that lipids of various lengths dif-
ferentially impact muscle AMP-K activity, consistent with the
observed muscle tissue lipid composition, increased activation
of AMP-K, and enhanced fatty acid oxidation in aP2-mal1-defi-
cient animals.
Protection against fatty liver disease
in aP2-mal1-deficient mice
The weight of the liver was reduced in the aP2-mal1−/− animals
on high-fat diet (Figure 6A). Consistent with the reduction in
liver weight, histological examination of liver sections revealed
a dramatic reduction in fatty infiltration in aP2-mal1−/− mice
compared to the wt animals (Figure 6B). In fact, the histopa-
thology of aP2-mal1−/− livers on high-fat diet was indistinguish-
able from livers of mice on regular diet.
Accumulation of lipids in the liver may involve several path-
ways. To approach the mechanisms underlying the protection
from fatty liver disease in the aP2-mal1−/− mice, we first bio-
chemically determined the liver triglyceride content. These
experiments demonstrated significantly lower liver tissue tri-
glyceride accumulation (Figure 6C) in the aP2-mal1−/− mice
compared to wt controls (1.28 ± 0.14 versus 1.89 ± 0.07 mg/Figure 6. FABPs role in liver lipid metabolism, hepatosteatosis, and SCD-1 activity
A) Total wet weight of liver tissue obtained from aP2-mal1−/− (AM−/−) and wt mice on high-fat diet.
B) Representative hematoxylin and eosin (H&E) stains of liver tissue (×100) sections from AM−/− and wt mice on high-fat diet prepared at 20 weeks of age.
C) Triglyceride content of liver tissue obtained from AM−/− and wt mice on high-fat diet.
D) Portal concentration of free fatty acids in AM−/− and wt mice on high-fat diet.
E) The effects of fatty acid chain length on lipid accumulation in Fao liver cells. Direct micrographs are shown after 48 hr treatment with the indicated fatty acids. The
quantitation in each experiment is shown as a percent of control in parenthesis.
F) Stearoyl-CoA desaturase-1 (SCD-1) expression in Fao cells treated with lipids and in liver tissue of AM−/− and wt mice on high-fat diet.
G) Total SCD activity in liver tissue of AM−/− and wt mice on high-fat diet. Error bars represent the SEM. Asterisk, p < 0.05.CELL METABOLISM : FEBRUARY 2005g, respectively, p < 0.05). This significant reduction in liver tri-
glyceride content and hepatosteatosis was not evident in
aP2−/− or mal1−/− mice (data not shown). Interestingly, the por-
tal free fatty acid levels were even higher in the aP2-mal1−/−
mice compared to wt controls on high-fat diet (Figure 6D). This,
along with the alteration in the liver lipid profile, suggests an
intracellular hepatic mechanism accounting for the lack of lipid
accumulation in liver cells.
The lipid profile seen in liver with accumulation of longer
chain fatty acids such as stearic acid is striking, since this
pattern was the opposite of lipid distribution detected in adi-
pose and muscle tissues where there was accumulation in fa-
vor of shorter chain fatty acids. To test the potential impact of
this lipid distribution on the development of hepatosteatosis,
we first tested the ability of lipids with various chain lengths to
accumulate in cultured liver cells. These experiments demon-
strate that fatty acid chain length is inversely correlated with
the ability to accumulate lipids in cultured liver cells where
longer chain (16:0 and 18:0) fatty acids essentially lacked the
ability to induce hepatosteatosis, therefore supporting the hy-
pothesis that lipid metabolism as well as composition might
underlie the lack of fatty liver disease in aP2-mal1-deficient
mice (Figure 6E). The lipid distribution pattern observed in the115
A R T I C L Elivers of aP2-mal1−/− mice led us to postulate that likely loci
that are affected might be fatty acid synthase (FAS) and/or ste-
aroyl-CoA desaturase-1 (SCD-1). Interestingly, SCD-1 expres-
sion in liver cells was strongly suppressed by fatty acids but
without the same clear and dramatic effect of chain length
seen in muscle (Figure 6F). Examination of SCD-1 expression
in the liver tissues of aP2-mal1−/− mice and wt controls on
high-fat diet also demonstrated a striking defect in the expres-
sion of SCD-1 in the liver tissue of aP2-mal1−/− animals (Figure
6F). This reduction in SCD-1 mRNA expression was associated
with a significant decrease in liver SCD activity (Figure 6G). In
contrast, there was no reduction in SCD activity in adipose
(3.17 ± 0.32 versus 2.89 ± 0.51 in wt and aP2-mal1−/− mice,
respectively) or muscle tissues (0.28 ± 0.04 versus 0.25 ± 0.04
in wt and aP2-mal1−/− mice, respectively). Interestingly, SCD-1
is recently reported to be the predominant peripheral target of
leptin in liver. Upon treatment with leptin, or in ob/ob mice
where leptin expression is transgenically reconstituted, SCD-1
expression in liver is strongly suppressed. However, the level
of regulation seen in aP2-mal1−/− mice is greater than what
has been achieved through leptin administration or transgenic
leptin production (Cohen et al., 2002; Soukas et al., 2000), sug-
gesting that its regulation may not be entirely related to leptin
action at this site.
Finally, we examined the expression patterns of other mole-
cules that are critical in liver lipid metabolism, including the
SREBP family of transcription factors, acetyl-CoA carboxylase
1 (ACC-1), and fatty acid synthase (FAS), to be able to con-
struct a better mechanistic model (Table S2). Among all of the
genes examined, the most dramatic regulation was for SCD-1
(96% reduction in aP2-mal1−/− mice). Interestingly, these ex-
periments also demonstrated reduction (70%) in liver SREBP1c
expression in aP2-mal1-deficient mice. Consistent with this,
we also detected moderate decreases in the expression of a
number of additional SREBP1 target genes critical in fatty acid
metabolism, including ACC-1, FAS, ELOVL6, SPOT14, HMG-
CoA reductase, and HMG-CoA synthase (Table S2). In con-
trast, no change was evident in the expression levels of
SREBP2, DGAT1, or mGPAT.
Discussion
Fatty acids have long been seen as critical components of the
pathogenesis of obesity and its associated disorders. However,
the mechanisms by which these or other lipids mediate these
abnormalities remain unclear. Our findings in this study demon-
strate that FABPs are critical in the interface between cellular
lipid trafficking and homeostasis and the peripheral signaling
pathways that are central to obesity and its associated pathol-
ogies. The deletion of two FABPs, aP2 and mal1, in mice
causes significant changes in lipid and hormone profiles and
leads to significant protection against obesity, insulin resis-
tance, type 2 diabetes, and fatty liver disease.
In FABP-deficient animals, there is an increase in the ratio of
shorter chain (C14) to longer chain (C18) fatty acids in adipose
and muscle tissues. This pattern is reflected in circulating lipids
but reversed in liver. We have presented several intermediary
mechanisms in this lipid environment that underlie the pheno-
type of the mice. First, we demonstrated the differential impact
of exposure to fatty acids of different chain length on muscle
insulin receptor signaling. These results are in line with previous116reports indicating the inhibitory effects of long chain fatty acids
on insulin action (Chavez and Summers, 2003). Consistent with
these findings, basal and insulin-stimulated phosphorylation of
Akt in FABP-deficient mice is also significantly increased in adi-
pose and muscle tissues, accompanied by increased insulin-
stimulated glucose uptake at both sites. Second, we demon-
strate that the lipid composition of muscle is altered to favor
shorter chain length fatty acids. This composition supports
higher levels of AMP-K activity in cultured cells and, consistent
with these observations, there is increased basal and stim-
ulated muscle AMP-K activity, fatty acid oxidation, and
increased energy expenditure in FABP-deficient mice. Conse-
quently, the overall triglyceride content of the muscle, a well-
established indicator of lipotoxicity, is also reduced in aP2-
mal1−/− animals, although the magnitude of this reduction is
moderate. Whether alterations in lipid uptake in muscle also
contribute to the muscle lipid composition and metabolism re-
mains to be determined. Third, we demonstrated a significant
reduction in liver SCD-1 expression and activity in FABP-defi-
cient animals accompanied by increased longer chain fatty
acids and striking resistance to fatty liver disease upon expo-
sure to a high-fat diet. These changes occur despite higher
systemic and portal fatty acid input. We also demonstrated the
differential impact of exposure to fatty acids of different chain
length on SCD-1 expression and the capacity to induce lipid
accumulation in liver cells. The reduction in SCD-1 expression
seen in FABP-deficient animals is highly relevant to their liver
phenotype, since genetic SCD-1 deficiency also results in
strong protection from hepatosteatosis and an overall pheno-
type reminiscent of FABP-deficient model presented here (Co-
hen et al., 2002). Finally, we demonstrate that aP2-mal1 defi-
ciency results in decreased SREBP1c expression in liver and a
consequent reduction in the transcriptional target genes for
this key transcription factor for liver lipid metabolism. This is a
likely response triggered by the elevated fatty acid levels deliv-
ered through the portal system to liver. Interestingly, however,
SREBP2 expression is not altered by FABP deficiency. It has
been shown that SREBP2 expression is upregulated in the liver
tissue of SREBP1c-deficient mice, leading to increased liver
cholesterol synthesis (Shimano et al., 1997). In the current
model, despite decreased SREBP1c expression, there is no
compensatory upregulation of SREBP2 in the liver tissue of
aP2-mal1-deficient mice, which also provides further protec-
tion from hepatosteatosis with decreased HMG-CoA reductase
and HMG-CoA synthase expression.
It is of note that both muscle AMP-K and liver SCD-1 have
recently been established as major targets for peripheral leptin
action. In this study, we also show data supporting enhanced
activation of AMP-Kα1 and α2 isoforms in the muscle tissue
of aP2-mal1−/− animals. Furthermore, AMP-K is also targeted
by adiponectin, and adiponectin-stimulated AMP-Kα1 activity
in muscle is also enhanced in aP2-mal1-deficient animals (data
not shown). These observations raise the interesting possibility
that at least part of the impact of FABPs on systemic metabo-
lism is either dependent on leptin and/or adiponectin activity
or mimicking peripheral actions of these molecules. Since there
were no recognizable changes in food intake but a significant
increase in energy expenditure in aP2-mal1−/− mice, we sug-
gest that the primary site of action in these animals is at the
periphery, whether or not it is dependent on leptin activity. Ad-CELL METABOLISM : FEBRUARY 2005
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address these questions further.
We demonstrate significant alterations in fatty acid transport,
availability, and composition upon loss of intracellular FABPs.
These activities have not been associated with cytosolic
FABPs in previous studies. Interestingly, since systemic free
fatty acid levels are not decreased in FABP deficiency, our data
supports the concept that transport and availability of fatty
acids to the target tissues and the intracellular responses elic-
ited by these lipids are more critical in determining the meta-
bolic outcomes than the absolute values present in circulation.
Regarding the latter, an interesting possibility remains that
FABPs might also alter stress and inflammatory responses, in-
cluding the activation of c-jun N-terminal kinase (Jnk) induced
by lipids and cytokines, as well as ER stress, which are criti-
cally coupled to both obesity and insulin resistance (Hirosumi
et al., 2002; Ozcan et al., 2004; Yuan et al., 2001). These obser-
vations should stimulate further interest in the important role
played by these proteins in cellular and systemic lipid homeo-
stasis.
In this study, we demonstrate that mice lacking the FABPs
aP2 and mal1 are remarkably resistant to diet-induced obesity,
fatty liver disease, insulin resistance, and type 2 diabetes.
These results also illustrate that the aP2-mal1−/− mice differ
from the individual deficiency of aP2 and mal1 in several re-
spects (Table 1). First, whereas aP2-mal1−/− mice are protected
from obesity, aP2- or mal1-deficient mice show no difference
in systemic adiposity (Maeda et al., 2003), and aP2−/− mice
actually gain more weight upon induction of dietary or genetic
obesity (Hotamisligil et al., 1996; Scheja et al., 1999; Uysal et
al., 2000). In addition, no difference in metabolic rates is ob-
served in aP2- or mal1-deficient animals, whereas aP2-mal1-
deficient animals exhibit increased O2 consumption and CO2
production. Second, the magnitude of the increase in insulin
sensitivity observed in aP2-mal1 deficiency significantly ex-
ceeds that of individual aP2 or mal1 deficiency. There are also
significant alterations in adipocytokine levels in aP2-mal−/−
mice. Third, neither aP2 nor mal1 deficiency provides signifi-
cant protection from hepatosteatosis, whereas this phenotype
is essentially completely corrected in aP2-mal−/− animals. Hence,
the molecular compensation observed in individual FABP defi-
ciency models has substantial physiological significance.
Finally, in our earlier studies, we have also observed that
FABP-deficient mice are dramatically protected against athero-
sclerosis through the action of these FABPs in macrophagesTable 1. Phenotypic comparison of single and combined FABP deficiency in mice
aP2−/− mal1−/− aP2-mal1−/−
Body weight [[ Y YYY
Total adiposity / / YYY
Hepatosteatosis / / YYYY
VCO2 / / [[
VO2 / / [[
ITT YY Y YYYY
GTT YY Y YYY
Leptin / / YYY
Adiponectin / / YY
The comparison represents the differences between genotypes in the context of dietary obesity. VCO2, carbon dioxide production; VO2, oxygen consumption; ITT,
insulin tolerance test; GTT, glucose tolerance test./, no change; [, increased; Y, decreased; number of arrows indicates magnitude of change.CELL METABOLISM : FEBRUARY 2005(Boord et al., 2002, 2004; Makowski et al., 2001). These results
clearly demonstrate that FABPs integrate metabolic and in-
flammatory responses in adipocytes and macrophages and
that they are central to the development of key pathologies
associated with metabolic syndrome. Taken together with the
impact of FABPs on atherosclerosis, results presented here il-
lustrate that blocking the activity of FABPs would constitute
novel and powerful therapeutic opportunities, which could be
exploited through straightforward biochemical assays based
on ligand replacement, in obesity and associated disorders
such as insulin resistance, type 2 diabetes, hepatosteatosis,
and cardiovascular disease.
Experimental procedures
Mice and dietary studies
Mice with homozygous null mutations in aP2 and mal1 (aP2-mal1−/−) were
generated from an intercross between aP2−/− and mal1−/− mice, which re-
sulted in double heterozygous mice and a subsequent crossing of aP2-
mal1−/+ animals with each other. All mice used in the study are males and
backcrossed >12 generations into the C57BL/6J genetic background. The
Institutional Animal Care and Use Committee (Harvard School of Public
Health) approved all studies. To investigate the role of FABP deficiency in
diet-induced obesity, we placed male, C57BL/6J-aP2−/−, C57BL/6J-mal1−/−,
C57BL/6J-aP2-mal1−/−, and C57BL/6J-wt control mice on a high-fat diet
(Diet F3282, Bioserve, NJ) in which 50% of the calories are provided in the
form of fat. This model of dietary obesity and insulin resistance is milder
than that of the genetic models and considered similar to the extent of
disease in the majority of humans (Uysal et al., 1997). Mice were placed on
this diet at 4 weeks of age and followed until week 20. A control group on
regular rodent diet was also included to determine the efficiency of the diet
and comparisons with the obese group.
Imaging studies
T2-weighted MR images were collected on a 4.7 T/40 cm horizontal bore
Varian MR imager. Mice were positioned in a 3.8 cm imaging volume coil.
The temperature inside the probe is maintained at 32°C. T2-weighted im-
aging experiments were performed using a spin echo multislice sequence
TR/TE = 2000/30 msec, 5 cm field of view, 128 × 128 matrix, and 2 mm
slice thickness for axial images. Slices were collected to cover the regions
of interest.
Metabolic studies
The details of indirect calorimetry and physical activity experiments are pro-
vided in the Supplemental Data. Tolerance tests were performed on male
mice after 6 hr daytime food withdrawal. Insulin and glucose solutions were
injected into peritoneal cavity at the dose of 0.5 U/kg and 1.0 mL/kg (1 M
solution), respectively. Blood was collected via tail vein at different time
points, and glucose levels were measured by the use of a glucometer
(Precision). Serum insulin, leptin, and adiponectin levels were measured117
A R T I C L Ewith RIAs for rat insulin and mouse leptin and adiponectin (Linco Research).
Serum lipid concentrations were determined by established assays as pre-
viously described (Maeda et al., 2003; Uysal et al., 2000).
Liver and muscle triglycerides, fatty acid analysis, and treatments
Soleus muscle was carefully dissected from mice to limit fat contamination.
Triglyceride in soleus muscle or liver tissue was determined using a com-
mercial kit (Determiner TG, Kyoma Medex, Japan). Total lipids were ex-
tracted from serum by the method of Dole and Meinertz (1960). Free fatty
acids were separated from esterified fatty acids by thin layer chromatogra-
phy using silica gel and a mixture of petroleum ether:diethyl ether: acetic
acid (80:20:1) as the stationary and mobile phases, respectively. Fatty acids
were methylated by incubation (50°C, 1 hr) with methanol/acetyl chloride
(20:1), evaporated, redissolved in isooctane, and separated by gas chroma-
tography. Individual fatty acids were identified by comparison to purified
standards. C2C12 myoblasts were cultured in DMEM containing 10% fetal
bovine serum, and differentiation was induced by DMEM supplemented
with 2% horse serum. Cells were treated with fatty acids, as described
(Chavez and Summers, 2003). On day 4 of differentiation, cells were incu-
bated with indicated fatty acid (0.75 mM in DMEM with 1% FBS, 2% BSA)
for 20 hr. Cells were changed into serum-free medium containing the same
fatty acid 4 hr prior to experiment and then treated with or without insulin
(100 nM, 10 min). L6 cells were cultured and differentiated as described
(Tong et al., 2001) and treated with fatty acids on day 7. Fao cells main-
tained in DMEM with 10% FBS were washed with PBS twice and treated
with free fatty acids in DMEM with 2% BSA for 24 hr.
Fatty acid binding and uptake assay
FA binding activity was determined as described (Glatz and Veerkamp,
1983) using Lipidex. The detailed protocol is provided in the Supplemental
Data. For uptake experiments, epididymal fat pads from five to six 12-week-
old mice were collected and digested with collagenase. The floating adipo-
cytes were washed three times with Krebs-Ringer phosphate isolation
buffer containing 20 mM HEPES (pH 7.4), 2.5% BSA, 200 µM adenosine,
and 5 mM glucose. Cell suspension (200 µl) was incubated with 3H-labeled
lauric, myristic, palmitic, or stearic acid at a final concentration of 100 µM
at 37°C for 30 min. Following the incubation, the uptake was terminated by
adding ice-cold stop solution containing 0.1% BSA and 200 µM phloretin
in isolation buffer. The cell suspension was then transferred onto a What-
man glass filter and washed three times with ice-cold PBS. The radioactivity
of the filters was measured by a liquid scintillation counter.
Glucose uptake, AMP-K enzyme activity, and fatty acid oxidation
Glucose uptake assays in muscle strips and primary adipocytes were per-
formed as described (Abel et al., 2001; Bruning et al., 1998). For AMP-K
enzyme assay, mice were housed in individual cages and, 5 days before
the experiment, indwelling catheters were implanted into the jugular vein.
Injection of leptin or saline was initiated from 9 to 10 a.m. (lights on, 6
a.m.). Food and water were available during the experiments. Recombinant
murine leptin (1 mg/kg body weight) (Peprotech) was injected intravenously
through the jugular vein catheter in mice anesthetized with ketamine (40
mg/kg) and xylazine (5 mg/kg) solution. Control mice received the same
volume of saline. After the mice were sacrificed, skeletal muscles were
rapidly dissected and frozen in liquid nitrogen. To measure isoform-specific
AMP-K activity, AMP-K was immunoprecipitated from muscle lysates (100
g of protein) with specific antibodies against the α1 or α2 catalytic sub-
units (gift of Dr. Carling) bound to protein G-Sepharose beads. Kinase activ-
ity was measured using synthetic “SAMS” peptide and [γ-32P]-ATP, as de-
scribed (Minokoshi et al., 2002). Fatty acid oxidation activity in muscle was
determined by a previously described method (Kaushik et al., 2001) with
modifications, which is detailed in the Supplemental Data.
SCD activity, immunoblotting, and gene expression analysis
SCD activity was determined from the production of 3H2O using [9, 10-3H]-
stearoyl-CoA as substrate (Gomez et al., 2002). Tissues were homogenized,
and the microsomal fractions (105,000 × g) were isolated by sequential cen-
trifugations. Reactions were performed at 37°C for 30 min with 100 µg/mL
protein homogenate, 10 µM (2 uCi/mL) of [9, 10-3H]-stearoyl-CoA (American
Radiolabeled Chemicals Inc.), and 30 µM NADH in 100 µl of 10 mM potas-
sium phosphate buffer (pH 7.4). After the reaction, 100 µl of 10 mg/mL fatty118acid-free BSA (Sigma) and 200 µl of 10% trichloroacetic acid were added
and then mixed. After centrifugation (5000 × g, 10 min), radioactive counts
in the supernatant were measured by a scintillation counter. The enzyme
activity was expressed as nmol min−1 mg−1 protein. FABP proteins were
detected by immunoblotting with antisera raised against full-length human
mal1 and aP2 in adipose tissue extracts prepared as described (Scheja et
al., 1999). Phosphorylation of the α subunit of AMP-K in soleus lysates
was determined with gradient SDS-PAGE gels using an antibody against
phosphopeptides based on the amino acid sequence surrounding Thr172
of either α1 and α2 isoforms of the catalytic subunit of AMP-K (Cell Signal-
ing). Protein levels of AMP-K were determined using an antibody for both
α1 and α2 subunits of AMP-K (Cell Signaling). AKT and phospho-AKT anti-
bodies were purchased from Cell Signaling. RNA extraction and gene ex-
pression studies are detailed in the Supplemental Data.
Statistical analysis
All numerical data were expressed as mean, and error bars represent the
SEM. Two-tailed, two-sample, unequal variance Student’s t tests were used
to assess statistical significance where p < 0.05 was the accepted level of
statistical significance.
Supplemental data
Supplemental Data include one figure, two tables, Supplemental Experi-
mental Procedures, and Supplemental References and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/1/2/107/
DC1/.
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